Second antibody for improvement of antibody imaging: liposome-entrapped and free preparations in animal and human studies.
When anti-tumour antibodies are given systematically for tumour imaging or therapy, second antibody directed against the first (anti-tumour) antibody can be used to accelerate clearance of first antibody, thus improving discrimination between tumour and normal tissues. Liposome-entrapped, and free second antibodies (LESA and FSA, respectively) have been compared in an animal tumour model system and in patients with cancer. Nude mice bearing xenografts of human colon carcinoma were given goat antibody to carcino-embryonic antigen (CEA) as first antibody and horse anti-goat second antibody. Patients with gastrointestinal carcinomas received i.v. 131I-labelled goat anti-CEA or mouse monoclonal 17-1A first antibody and unlabelled horse angi-goat or rabbit anti-mouse second antibody, respectively. Antibody distribution was studied by serial gamma camera imaging. The effectiveness of LESA and FSA depended on dose. Tumour-to-blood ratios were increased up to eight-fold by either method in animals. Tumour imaging was enhanced among 15 patients with gastrointestinal cancer and tumour was correctly identified at five sites where it was not seen by a background subtraction method. No significant toxicity occurred in patients nor in rabbits studied for evidence of immune complex mediated disease. LESA and FSA appear to be equally effective.
Begent
H J
HJ
Department of Medical Oncology, Charing Cross and Westminster Medical School, London, England.
Chester
K A
KA
Bagshawe
K D
KD
Keep
P A
PA
Searle
F
F
Boden
J
J
Barratt
G M
GM
Green
A J
AJ
Riggs
S J
SJ
Woodrow
D F
DF
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage* / Q000009:adverse effects; D000912:Antibodies, Neoplasm / Q000009:adverse effects; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging; D006041:Goats; D006736:Horses; D006801:Humans; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D011817:Rabbits; D016719:Radioimmunodetection / Q000009:adverse effects / Q000379:methods*
D000888:Antibodies, Anti-Idiotypic; D000912:Antibodies, Neoplasm; D008081:Liposomes